Brooks Laboratories amends AGM resolution for ₹48.15 crore BSL guarantee

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Brooks Laboratories issued an addendum on August 22, 2026, for its September 3 AGM
  • Resolution 4 amended to ratify ₹48.15 crore guarantee for joint venture BSL
  • Proposed FY27 related-party transaction limits total ₹35 crore plus guarantee
  • Aggregate exposure represents 96.99% of prior year consolidated turnover
powered bylight_fuzz_icon
47661444

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories Limited issued an addendum on August 22, 2026, to the notice of its 24th Annual General Meeting (AGM), scheduled for September 3, 2026. The update amends Resolution No. 4 to align with corporate guarantee arrangements involving its jointly controlled entity, Brooks Steriscience Limited (BSL). The company published the addendum in Financial Express and Jansatta on August 22, 2026.

The original AGM notice, dated July 31, 2026, and dispatched on August 12, 2026, remains valid except for the modifications detailed in the addendum. Shareholders must read the addendum collectively with the initial notice and the Annual Report for FY25-26.

Related Party Transaction Details

The amendment seeks shareholder approval to ratify a corporate guarantee of ₹48.15 crore provided in favor of BSL during March 2026. This guarantee was approved by the Audit Committee in its meeting held on February 6, 2026. The company proposes an overall corporate guarantee limit of up to ₹48.15 crore for BSL. Any further guarantees will require enhancement of this limit and applicable approvals.

In addition to the guarantee, the company proposes to continue operational transactions with BSL during FY26-27:

  • Purchase of goods and commissions: up to ₹15 crore
  • Sale of goods and commissions: up to ₹15 crore
  • Job work services and shared services: up to ₹5 crore

The aggregate value of these transactions, including the corporate guarantee limit, represents approximately 96.99% of the company’s annual consolidated turnover for the immediately preceding financial year. Atul Ranchal is identified as a related party director interested in these transactions.

Other AGM Resolutions

The AGM agenda includes several other key resolutions:

  • Cost Auditor Ratification: Ratification of remuneration payable to M/s. Balwinder & Associates for FY26-27 cost audit, amounting to ₹60,000 plus taxes.
  • Director Reappointment: Reappointment of Mr. Jitendrapratap Rambahadur Singh, who retires by rotation.
  • Executive Remuneration: Approval of remuneration for Mr. Atul Ranchal, President – Strategy, at a maximum of ₹15 lakh per month, effective September 1, 2026. Additionally, remuneration for Mr. Rajesh Mahajan, President – Trading, at a maximum of ₹8 lakh per month, effective July 17, 2026.

Key Dates and Logistics

The Register of Members will remain closed from August 27, 2026, through September 3, 2026. Remote e-voting opens on August 31, 2026, at 9:00 am and closes on September 2, 2026, at 5:00 pm. The AGM will be conducted exclusively via Video Conferencing or Other Audio-Visual Means (VC/OAVM), starting at 9:00 am IST.

Event Date/Time Mode
AGM Date September 3, 2026 VC/OAVM
Start Time 9:00 am IST Virtual
Book Closure Start August 27, 2026 N/A
Book Closure End September 3, 2026 N/A
E-Voting Cut-Off August 27, 2026 N/A
Remote E-Voting Start August 31, 2026, 9:00 am IST Online
Remote E-Voting End September 2, 2026, 5:00 pm IST Online

Shareholders are advised to ensure their email addresses are registered with their Depository Participants or the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, to receive communications electronically. Attendance via VC/OAVM counts toward the quorum requirement under Section 103 of the Companies Act, 2013.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.88%+2.40%+9.67%+5.15%-56.59%0.0%

How might the high concentration of related-party transactions, representing nearly 97% of turnover, impact Brooks Laboratories' operational independence and risk profile in FY26-27?

What are the specific strategic growth drivers for Brooks Steriscience Limited that justify the ₹48.15 crore corporate guarantee and continued financial support from the parent company?

Will the approved remuneration increases for President Atul Ranchal and President Rajesh Mahajan correlate with specific performance targets or expansion goals for the Strategy and Trading divisions?

Brooks Laboratories Ltd appoints Rajesh Mahajan as President

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights

Brooks Laboratories Ltd appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel effective July 17, 2026. The company disclosed the appointment under Regulation 30 of the SEBI Listing Regulations. Mr. Mahajan brings over 20 years of experience in the pharmaceutical industry.

powered bylight_fuzz_icon
45838074

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories Ltd has appointed Mr. Rajesh Mahajan as President - Trading and Senior Management Personnel effective July 17, 2026. The appointment aims to leverage his extensive expertise in pharmaceutical formulations and manufacturing operations to drive the company's formulation business and new project initiatives.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted the required details in compliance with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He possesses over 20 years of experience in the pharmaceutical industry, with a specific focus on formulations and manufacturing operations. His previous contributions include playing a key role in the growth of Brooks Laboratories 's formulation business and executing business development strategies.

The appointment details were formally communicated to BSE Limited and the National Stock Exchange of India Ltd. The information has been made available on the company's official website.

Key Appointment Details

Particulars Details
Name of SMP and designation Mr. Rajesh Mahajan - President Trading
Reason for change Appointment
Date of appointment July 17, 2026
Brief profile Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He has over 20+ years of experience in the pharmaceutical industry, with extensive expertise in pharmaceutical formulations and manufacturing operations.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+2.88%+2.40%+9.67%+5.15%-56.59%0.0%

What specific new project initiatives will Mr. Mahajan prioritize following his appointment?

How will this leadership change impact Brooks Laboratories' revenue growth in the formulation business over the next fiscal year?

Will the company expand its manufacturing capacity to support the anticipated growth under Mr. Mahajan's direction?

More News on Brooks Laboratories

1 Year Returns:-56.59%